House Judiciary Committee Advances Four Drug Pricing Bills, Although Changes Are Still Likely
US committee will likely re-examine the language regarding the burden of proof in a bill prohibiting pay-for-delay settlements.
You may also be interested in...
Governor Newsom signs bill that presumes brand-generic patent settlements are anticompetitive; AAM says the law violates US Constitution by attempting to regulate transactions outside the state.
Pricing transparency legislation requests too much information, Republicans say during hearing in US House Energy and Commerce Subcommittee on Health.
CREATES Act and 180-day exclusivity reforms also in legislation headed to US House floor, even as generic industry remains opposed to two of the three main provisions. The Rx pricing language is bundled with Obamacare language designed to force a tough vote by Republicans.